Visiting Shanghai to Attract Investment: TEDA Biopharmaceutical Cooperation Exchange Conference Held in Shanghai

On the afternoon of December 16th, the "Development Strategy in China for Pharma and Medical Devices Multinationals——Exchange Conference on Tianjin Local Policies Interpretation, M&A and Cooperative Innovation ," jointly organized by the American Chamber of Commerce in Shanghai and the TEDA Administrative Commission, was held in Shanghai. Through policy interpretations on biopharmaceuticals, regional comprehensive presentations, case studies from multinational corporations, and on-site networking exchanges, the conference aimed to help foreign-invested enterprises accurately grasp policy directions, seize market opportunities, and collaborate with TEDA to promote high-quality development in the biopharmaceutical industry. Representatives from over 60 multinational corporations and institutions, including Medtronic, Danaher, Roche Diagnostics, GE Healthcare Financial Services, Sekisui Medical, and Kenvue , attended the event.

This exchange conference marks the first meeting held after the upgrade of TEDA’s Shanghai Office to the TEDA Yangtze River Delta Industrial Empowerment and Coordination Center. The center is a thoughtfully designed, multifunctional space that integrates exhibition, communication, and event hosting, tailored to meet the current practical needs of investment promotion in the Yangtze River Delta region. It aims to enhance regional promotion and empower targeted investment attraction. The exchange conference established an efficient and practical platform for communication between TEDA and multinational biopharmaceutical enterprises, effectively showcasing TEDA and Tianjin’s biopharmaceutical industry and development opportunities, thereby boosting multinational companies’ confidence in investing in Tianjin. During the event, several multinational companies engaged in in-depth discussions with TEDA’s investment promotion team and expressed their willingness to explore further cooperation. In the future, TEDA will continue to optimize its innovation ecosystem, enhance service efficiency, promote the innovative development of the biopharmaceutical industry, and provide a broader development platform for global enterprises.